ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0239

Neutralising Antibody Responses to Bivalent SARS-CoV-2 Vaccines and Hybrid Immunity in Patients on TNF Inhibitors: A Prospective Cohort Study
Abstract Number: 0801

Neutrophil Activation as a Novel Marker of Lung Disease in Rheumatoid Arthritis
Abstract Number: 0507

Neutrophil Activation Markers Can Predict Rheumatoid Arthritis Treatment Response to the Janus Kinase 1/2 Inhibitor Baricitinib
Abstract Number: 1268

Neutrophil Lymphocyte Ratio as a Novel Marker of Skin Disease Activity in Older Children with Juvenile Dermatomyositis
Abstract Number: 0766

Neutrophil Transcriptomics in VEXAS Syndrome
Abstract Number: 1581

Neutrophil-to- lymphocyte Ratio: A Possible Biomarker for Clinical Response After Autologous Hematopoietic Stem Cell Transplantation
Abstract Number: 0185

New and Severe Damage in a Prevalent Lupus Cohort Through the Lens of Demographic and Neighborhood Disparities
Abstract Number: 0470

New Approach for Early and Accurate Diagnosis of Rheumatoid Arthritis-related Interstitial Lung Disease: Matrix Metalloproteinases 7 and 9 as Novel Blood Biomarkers
Abstract Number: 1576

New Patient-Reported Outcome Measures for Early Systemic Sclerosis Using the FDA Guidance on Patient Reported Outcome Measures
Abstract Number: 0193

New York City Lupus Clinical Trials Education Program
Abstract Number: 1780

Next Generation Sequencing Analysis Reveals Complex Genetic Architecture of Childhood-onset Systemic Lupus Erythematosus
Abstract Number: 0912

Next-Generation Sequencing in Molecular Genetics of Adult-Onset Still’s Disease: Data from 23 Patients and Literature Review
Abstract Number: 0836

NF-κB Inducing Kinase Is a Therapeutic Target for Autoimmune Diseases by Orchestrating Both B Cell and T Follicular Helper Cell Responses
Abstract Number: 1114

Nintedanib in Autoimmune Disease-related Interstitial Lung Disease: Real-life Effectiveness, Safety and Tolerance in a Spanish Multicenter Study
Abstract Number: 0933

NLRP3 Inflammasome Promotes Release of Peptidyl Arginine Deiminases2 and 4 from Human Neutrophils

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].